Oligonucleotide synthesis, often shortened to “oligo synthesis,” is the chemical process of building short, single-stranded pieces of DNA or RNA one base at a time. These synthetic strands are typically fewer than 100 bases long and serve as essential tools across molecular biology, diagnostics, and drug development. The process happens on automated machines called synthesizers, which assemble a custom DNA sequence in a matter of hours using a well-established cycle of chemical reactions.
How the Synthesis Cycle Works
Nearly all oligo synthesis today relies on a method called phosphoramidite chemistry, developed in the 1980s. The process builds the DNA strand in reverse compared to how cells naturally copy DNA, adding each new base from the 3′ end toward the 5′ end. The first base starts already attached to a tiny bead of controlled pore glass (CPG) or polystyrene packed inside a column. From there, each new base is added through a four-step chemical cycle that repeats for every position in the sequence.
Step 1: Deprotection. Each base on the growing strand has a chemical cap (called a DMT group) that prevents it from reacting prematurely. An acid wash removes this cap, exposing a reactive site on the strand that’s ready to accept the next base.
Step 2: Coupling. The next base in the desired sequence is flushed into the column as an activated building block. It’s delivered in large excess to push the reaction as close to 100% completion as possible. The incoming base bonds to the exposed end of the growing strand, extending it by one position.
Step 3: Oxidation. The chemical bond formed during coupling is initially unstable. A quick treatment with iodine converts it into the sturdy phosphate linkage found in natural DNA.
Step 4: Capping. No coupling step is perfectly efficient. A small fraction of strands fail to add the new base each cycle. If left alone, these incomplete strands would continue growing in later cycles with a missing base, creating a messy mixture of wrong-length products. The capping step blocks those failed strands so they can’t participate in further reactions, keeping them from contaminating the final product.
This four-step cycle repeats once for every base in the desired sequence. For a 25-base oligo, the machine runs 25 cycles. Once synthesis is complete, the finished strand is chemically cleaved from the solid support bead and treated with a strong base to remove all remaining protective groups.
Why Length Matters
Even with coupling efficiencies above 99% per cycle, errors compound over longer sequences. If each step succeeds 99% of the time, a 20-base oligo yields about 82% full-length product. Stretch that to 100 bases and the theoretical yield drops to around 37%. In practice, synthesizers reliably produce oligos up to about 125 to 150 bases before the amount of correct, full-length product becomes vanishingly small. Researchers who need longer sequences typically synthesize overlapping shorter oligos and stitch them together using PCR or enzymatic assembly.
Purification After Synthesis
The raw product coming off a synthesizer contains a mixture of full-length strands, shorter failure sequences (from capping), and leftover chemical reagents. How aggressively you purify depends on what you plan to do with the oligo.
- Desalting is the simplest cleanup. It removes salts and small chemical byproducts, yielding oligos that are roughly 80% pure. This is sufficient for many routine applications like standard PCR.
- HPLC purification separates molecules based on their chemical properties, offering higher resolution. It removes both failure sequences and internal deletions, making it the preferred method for applications that demand precision, such as antisense studies or quantitative experiments.
- PAGE purification separates strands strictly by size using a gel matrix, routinely achieving greater than 90% purity. It’s the gold standard for applications like cloning, site-directed mutagenesis, and next-generation sequencing library preparation. The tradeoff is significantly lower final yield and longer processing time.
Verifying the Final Product
Once an oligo is synthesized and purified, its identity needs to be confirmed. Mass spectrometry is the primary tool for this. Techniques like MALDI-TOF (matrix-assisted laser desorption ionization with time-of-flight detection) and ESI (electrospray ionization) measure the molecular weight of the oligo with enough precision to confirm it matches the expected sequence. MALDI-TOF is especially common for short oligos of 25 bases or fewer, where a “ladder sequencing” approach can verify the order of bases by progressively digesting the strand with enzymes and measuring the mass at each step. These methods can detect errors as small as a single missing or substituted base.
Common Chemical Modifications
One of the most powerful aspects of synthetic oligos is the ability to incorporate chemical modifications that natural DNA doesn’t have. These modifications are added during or after synthesis by swapping in specialized building blocks.
Phosphorothioate backbones replace one oxygen atom in the DNA backbone with sulfur. This small change makes the oligo highly resistant to enzymes that would normally chew up unprotected DNA in a cell, which is why phosphorothioate modification is the backbone of most oligonucleotide-based drugs. Fluorescent labels (fluorophores) attached to one end of an oligo allow researchers to track it visually, which is essential for diagnostic probes like TaqMan probes used in quantitative PCR. Biotin tags let an oligo be captured on a surface coated with the protein streptavidin, useful for pull-down assays and target enrichment. Amino groups, thiol groups, and various dye molecules can also be incorporated depending on the downstream application.
What Synthetic Oligos Are Used For
PCR primers are by far the most common application. Every PCR reaction requires two short oligos that flank the DNA region you want to amplify. Billions of these are synthesized worldwide each year. Beyond basic PCR, synthetic oligos serve as probes in quantitative PCR (qPCR), where dual-labeled oligos carrying both a fluorescent reporter and a quencher molecule allow researchers to measure exactly how much of a specific DNA target is present in a sample. This technique is used extensively in microbiology to quantify bacterial, archaeal, and fungal communities by targeting conserved genes.
In genome editing, the guide RNAs that direct CRISPR systems to their target are often produced as synthetic oligos. Gene synthesis, where researchers build entire genes from scratch, starts with overlapping oligos that are assembled into longer sequences. Diagnostic tests for infectious diseases, including many COVID-19 tests, rely on synthetic oligo primers and probes. And in therapeutics, synthetic oligos have become a drug class in their own right.
Oligonucleotide Therapeutics
As of April 2025, the FDA has approved 22 oligonucleotide-based drugs. These include antisense oligonucleotides that bind to messenger RNA to silence disease-causing genes, and small interfering RNA (siRNA) drugs like patisiran (Onpattro), which uses RNA interference to treat a hereditary nerve disorder. There is also an approved aptamer, pegaptanib (Macugen), which folds into a shape that binds and blocks a protein involved in abnormal blood vessel growth in the eye. The phosphorothioate backbone modification and specialized delivery systems like lipid nanoparticles have been critical to making these drugs survive long enough in the body to work.
Enzymatic Synthesis as an Alternative
Traditional phosphoramidite chemistry relies on harsh organic solvents and generates chemical waste. A newer approach uses an enzyme called terminal deoxynucleotidyl transferase (TdT), a natural polymerase that adds bases to the end of a DNA strand without needing a template. In enzymatic synthesis, TdT is combined with a second enzyme called apyrase that degrades unused building blocks after each addition step, limiting how many bases get added per cycle. The process runs in water-based solutions at mild temperatures, making it more environmentally friendly.
Enzymatic synthesis is particularly promising for DNA data storage, where information is encoded not in exact sequences but in the transitions between different base types. The technology is still maturing for applications that demand exact single-base control, but engineered versions of TdT that accept chemically modified bases with built-in stop signals are closing that gap.